Continuous-infusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis

P and T

Volumn 36, Issue 11, 2011, Pages 723-740

  Prescott, William A ^a   Gentile, Allison E ^b   Nagel, Jerod L ^c   Pettit, Rebecca S ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b CHILDREN S HOSPITAL OF BUFFALO   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Beta lactam; Continuous infusion; Cystic fibrosis; Infectious disease; Intermittent infusion; Monobactam; Pulmonary; Pulmonary exacerbation

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; DORIPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM ISOLATE; BODY TEMPERATURE; BREATHING EXERCISE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG STABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEMOPTYSIS; HUMAN; INFUSION PUMP; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; LUNG FUNCTION; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NAUSEA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; SIDE EFFECT; TONSILLITIS;

EID: 83255189569     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bui KQ, Ambrose PG, Nicolau D P, et al. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy 2001;47:153-156.
2. Christensson BA, Ljungberg B, Eriksson L, Nilsson-Ehle I. Phar-macokinetics of meropenem in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998;17:873-876.
3. Goss CH, Burns JL. Exacerbations in cystic fibrosis: Epidemiology and pathogenesis. Thorax 2007;62:360-367.
4. Conway S P, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003;2:321-332.
5. van Westreenen M, Tiddens HA. New antimicrobial strategies in cystic fibrosis. Paediatr Drugs 2010;12:343-352.
6. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
7. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
8. Drusano GL. Antimicrobial pharmacodynamics: Critical inter -actions of 'bug and drug.' Nat Rev Microbiol 2004;2:289-300.
9. Jacobs MR. Optimisation of antimicrobial therapy using phar-macokinetic and pharmacodynamic parameters. Clin Micro boil Infect 2001;7:589-596.
10. Zobell JT, Young DC, Waters CD, et al. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011;46:987-990.
11. Lacy CF, Armstrong LL, Goldman M P. Drug Information Handbook: A Comprehensive Resource for all Clinicians and Healthcare Professionals, 19th ed. Hudson, Ohio: Lexi-Comp, 2010.
12. Henwood CJ, Livermore DM, James D, Warner M. Antimicrobial susceptibility of Pseudomonas aeruginosa: Results of a UK survey and evaluation of the British Society for Antimicrobial Chemo -therapy disc susceptibility test. J Antimicrob Chemother 2001; 47:789-799.
13. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-796.
14. Taccetti G, Campana S, Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: The results of an Italian multicenter study. Eur J Epidemiol 1999;15:85-88.
15. Byl B, Baran D, Jacobs F, Herschuelz A, Thys J P. Serum phar-macokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001;48:325- 327.
16. Hayes D, Kanga JF, Anstead MI, Kuhn RJ. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Pediatr Pulmonol 2008;43:511-513.
17. Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009;53:3650-3656.
18. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;2:385.
19. Rappaz I, Decosterd LA, Bille J, et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000;159:919-925.
20. Vinks AATMM, Brimicombe RW, Heijerman HGM, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology, and pharmacokinetics. J Antimicrob Chemother 1997;40:125-133.
21. Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharma-cotherapy 1999;19:620-626.
22. Bulik CC, Quintiliani R Jr, Samuel Pope J, et al. Pharmaco -dynamics and tolerability of high-dose, prolonged infusion carba -penems in adults with cystic fibrosis: A review of 3 cases. Respir Med CME 2010;3:146-149.
23. Han EE, Beringer PM, Falch P, et al. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J Anti -microb Chemother 2006;57:1017-1019.
24. Reed MD, Aronoff SC, Stern RC, et al. Single-dose pharmaco -kinetics of aztreonam in children with cystic fibrosis. Pediatr Pulmonol 1986;2:282-286.
25. Vinks AA, van Rossem RN, Mathot RA, et al. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob Agents Chemother 2007;51:3049-3055.
26. Bulitta JB, Duffull SB, Kinzig-Schippers M, et al. Systematic comparison of the population pharmacokinetics and pharmaco -dynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007;51:2497-2507.
27. Reed MD, Stern RC, Myers CM, et al. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987;3:101-109.
28. Vinks AA, Den Hollander JG, Overbeek SE, et al. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 2003;47:541-547.
29. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;1:1454-1455.
30. Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37:418-423.
31. Vinks AATMM, Touw DJ, Heijerman HGM, et al. Pharmaco kinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994;16:341-348.
32. Leeder JS, Spino M, Isles AF, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther 1984;36:355-362.
33. Arguedas AG, Stutman HR, Zaleska M, et al. Cefepime: Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child 1992;146:797-802.
34. Hamelin BA, Moore N, Knupp CA, et al. Cefepime pharmaco kinetics in cystic fibrosis. Pharmacotherapy 1993;13:465-470.
35. Huls CE, Prince RA Seilheimer DK, Bosso JA Pharmaco kinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993;37:1414-1416.
36. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004;26:493-501.
37. Bulitta JB, Landersdorfer CB, Huttner SJ, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010;54:1275-1282.
38. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibro sis, and patients in the intensive care unit. Clin Ther 2005;27:762-772.
39. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal (beta)-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46:2327-2332.
40. Plasse JC, Chabloz C, Terrier A, Bellon G. Is it safe to administer a continuous infusion of ceftazidime (Fortum) prepared for 24 hours in cystic fibrosis (CF) patients (letter)? Pediatr Pulmonol 2002;33:232-233.
41. Arlicot N, Rochefort GY, Schlecht D, et al. Stability of antibiotics in portable pumps used for bronchial superinfection: Guidelines for prescribers. Pediatrics 2007;120:1255-1259.
42. U.S. Pharmacopeia Convention, 1995. United States Pharmacopeia/The National Formulary. Rockville, Md.: USP 23-NF 18.
43. Baririan N, Chanteux H, Viaene E, et al. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to admini stration in intensive care units. J Antimicrob Chemother 2003;51:651-658.
44. Couldry R Sanborn M, Klutman NE, Strayer AH. Continuous infusion of ceftazidime with an elastomeric infusion device. Am J Health Syst Pharm 1998;55:145-149.
45. Keel RA, Sutherland CA, Crandon JL. Stability of doripenem, imipenem, and meropenem at elevated room temperatures. Int J Antimicrob Agents 2011;37:184-185.
46. Crandon JL, Sutherland C, Nicolau DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am J Health Syst Pharm 2010;67:1539-1544.
47. Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010;65:1073-1075.
48. ®, version 61127 (updated February 2009). Greenwood Village, Col.: Thomson; 2009.
49. Thornton J, Elliott RA, Tully MP, et al. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: Comparing hospital and home care. J Cyst Fibros 2005;4:239-247.
50. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res 2003;12:63-76.